Panel: Closing the health inequity gap - access and outcomes

Panel: Closing the health inequity gap - access and outcomes

Wednesday, March 13, 2024 2:00 PM to 2:40 PM · 40 min. (Europe/London)

Information

  • To what extent has the NHS LTP successfully reduced inequalities and regional variations in care and outcomes?
  • Adopting a data led approach in expanding targeted screening such as the Targeted Lung Health Check Programme
  • Evaluating drivers of health inequalities which aren’t easily measured or uncovered through traditional data-led approaches
  • Introducing direct patient representation from the communities which are underrepresented, raising awareness of specific issues faced and closing the inclusivity gap
    Moderator: Julian Cole, Medical Director, UK & Ireland, Gilead Life Sciences
    Panellists:
    Femi Odewale, Managing Director, North East London Cancer Alliance
    Jonathan Ferguson, Consultant Cardiothoracic Surgeon & Cancer Lead, South Tees NHS FT
    Ruw Abeyratne, Director of Health Equality and Inclusion, University Hospitals of Leicester
    Stewart O’Callaghan, Founder & CEO, OUTpatients
GileadGileadGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Log in

See all the content and easy-to-use features by logging in or registering!